313 completed, 52 recruiting, 45 terminated, 42 unknown. 141 Phase 3, 137 Phase 2, 69 Phase 1, 40 Phase 4, 32 Not applicable.
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt No intervention - Hereditary Angioedema (HAE) | Not yet recruiting | Takeda | 100 | 2026-12-01 | 2026-06-18 | |
| A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria AK139, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Akeso | 201 | 2026-10-21 | 2026-10-15 |
| A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria MG-K10 Injection, Matching Placebo - Chronic Urticaria, Idiopathic | Phase 2 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 60 | 2026-09-23 | 2026-09-24 |
| Apremilast Added to Antihistamines in Chronic Urticaria Apremilast, Second-generation H1 antihistamine - Chronic Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Enrolling by invitation | Rashid Latif Medical College | 86 | 2026-09-23 | 2026-09-30 |
| Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks Remibrutinib, Omalizumab - Chronic Spontaneous Urticaria | Phase 3 | Recruiting | Novartis Pharmaceuticals | 382 | 2026-09-21 | 2026-10-13 |
| A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea No intervention - Hereditary Angioedema (HAE) | Recruiting | Takeda | 35 | 2026-09-21 | 2026-10-15 | |
| A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs TLL-018 tablets, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 140 | 2026-09-10 | 2026-08-24 |
| A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU) THB335 Lower Dose, THB335 Higher Dose, Placebo - Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria | Phase 2 | Not yet recruiting | Calixis Inc. | 81 | 2026-09-01 | 2026-08-17 |
| A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology Flexible ePROM-guided Scheduling System, electronic patient reported outcome measures (ePROMs) - Chronic Dermatological Conditions, Eczema | Not applicable | Not yet recruiting | National University Hospital, Singapore | 250 | 2026-09-01 | 2026-07-01 |
| Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) KVD900 600 mg - Hereditary Angioedema | Phase 4 | Recruiting | KalVista Pharmaceuticals, Ltd. | 100 | 2026-08-17 | 2026-09-17 |
| A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines TLL-018, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 1 / Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 36 | 2026-08-15 | 2026-08-24 |
| Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT) Chronic Spontaneous Urticaria | Recruiting | Novartis Pharmaceuticals | 470 | 2026-08-04 | 2026-08-07 | |
| A Trial of HRS-3095 in Healthy Volunteers HRS-3095 - Chronic Spontaneous Urticaria | Early Phase 1 | Recruiting | Atridia Pty Ltd. | 36 | 2026-07-27 | 2026-08-07 |
| A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria HRS-3095 Tablet, HRS-3095 Tablet Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 190 | 2026-07-01 | 2026-05-29 |
| Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2). Alpha-0261, Placebo - Chronic Spontaneous Urticaria (CSU), Healthy Volunteers | Phase 1 | Not yet recruiting | AlphaMol Science Ltd. (Shanghai) | 48 | 2026-07-01 | 2026-07-06 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) BBT001, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Recruiting | Bambusa Therapeutics | 48 | 2026-06-29 | 2026-07-22 |
| Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief 10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Anti-Pruritic Gel - Skin Pruritus, Itch | Not applicable | Completed | Nakhia Impex LLC | 30 | 2026-06-20 | 2026-09-22 |
| A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema Technochrom C1-INH Kit - Hereditary Angioedema (HAE) | Not applicable | Recruiting | Takeda | 514 | 2026-05-12 | 2026-05-19 |
| A Prospective, Single-centre, Observational Cohort Study on the Efficacy and Safety of Bacterial Lysate (OM-85) in Combination With Antihistamines for the Treatment of Chronic Spontaneous Urticaria (CSU) Chronic Spontaneous Urticaria (CSU) | Not yet recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 132 | 2026-05-01 | 2026-05-07 | |
| A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia No intervention - Hereditary Angioedema (HAE) | Recruiting | Takeda | 50 | 2026-04-30 | 2026-05-11 |
Showing 20 of 528. Sign in to see all of them.
Chronic Urticaria (191) · Angioedemas, Hereditary (169) · Angioedema (64) · Cryopyrin-Associated Periodic Syndromes (35) · Hypersensitivity (23) · Pruritus (23) · Asthma (17) · Chronic Inducible Urticaria (17) · Hereditary Angioedema Types I and II (17) · Cold Urticaria (16) · Rhinitis, Allergic (16) · Dermatitis, Atopic (14) · Skin Diseases (13) · Familial dermographism (9)
Skin and Connective Tissue Diseases (528) · Hypersensitivity, Immediate (522) · Skin Diseases, Vascular (522) · Immune System Diseases (519) · Skin Diseases (515) · Hypersensitivity (505) · Pathological Conditions, Signs and Symptoms (267) · Pathologic Processes (252) · Disease Attributes (246) · Chronic Disease (237) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (221) · Cardiovascular Diseases (213) · Vascular Diseases (213) · Genetic Diseases, Inborn (212)
Omalizumab (44) · Complement C1 Inhibitor Protein (28) · desloratadine (18) · icatibant (15) · levocetirizine (15) · lanadelumab (13) · remibrutinib (13) · berotralstat (12) · canakinumab (12) · conestat alfa (11) · Sodium Chloride (10) · ligelizumab (10) · bilastine (9) · sebetralstat (9) · SERPING1 protein, human (8)
Novartis Pharmaceuticals (48) · Shire (40) · Takeda (20) · BioCryst Pharmaceuticals (17) · CSL Behring (15) · Charite University, Berlin, Germany (15) · KalVista Pharmaceuticals, Ltd. (13) · Organon and Co (11) · Genentech, Inc. (10) · Celldex Therapeutics (8) · Pharming Technologies B.V. (8) · Pharvaris Netherlands B.V. (8) · University Hospital, Grenoble (8) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Ionis Pharmaceuticals, Inc. (6)
United States (208) · Germany (151) · France (91) · Canada (89) · Spain (83) · United Kingdom (80) · Italy (68) · Poland (67) · Hungary (51) · Japan (48) · China (47) · Netherlands (47) · Australia (46) · Bulgaria (42) · Israel (42)
Marcus Maurer, MD (7) · Anurag Relan, MD (4) · Jill A Poole, MD (3) · Lauge Farnaes, MD (3) · M. M. Levi, Prof. Dr. (3) · Marcus Maurer, Prof. (3) · Peter Bauer, MD (3)
PMID 36326435, PMID 36408587, PMID 20818886, PMID 23312695, PMID 23878046, PMID 24712435, PMID 23548529, PMID 26054553, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 29655772, PMID 42159953, PMID 42268494, PMID 17021840, PMID 20818888, PMID 20819318, PMID 20920772, PMID 21130380, PMID 22765833, PMID 22856635, PMID 23484892, PMID 23548526, PMID 23987198, PMID 25104279, PMID 25198193, PMID 28284978, PMID 31161734, PMID 34773261, PMID 36153561, PMID 36440464, PMID 36774155, PMID 37028510, PMID 38008109, PMID 39193419, PMID 40043237, PMID 40171989, PMID 40380356, PMID 40469312, PMID 40769455, PMID 40886933, PMID 42297099, PMID 42318595, PMID 12384926, PMID 12874849, PMID 14982513, PMID 15201414, PMID 15208377, PMID 15334472
2019 (10), 2023 (7), 2018 (6), 2015 (5), 2014 (4), 2009 (3), 2017 (3), 2025 (3), 2004 (2), 2008 (2), 2016 (1), R01AI116658 (1), R01HL079184 (1), R01HL082925 (1), ZIAAR041138-08 (1)